Using some naive assumptions here (that the average weight loss required for the average obese persons BMI to be below 30 and thus not categorized as obese, assuming x% of obese people take the drug and all experience the average reduction in body weight), we can see a picture emerge that shows the potential to disrupt a trend thats been forming for the past 50 years
counteract acrylamide-induced liver toxicity through suppression of NLRP3 inflammasome/NF-B axis
What makes this antioxidant it so powerful is its presence in every type of cell, including the immune system
However, the challenge with current TRPV1 antagonists lies in their associated adverse effects, such as hyperthermia 24,25,26,27,28,29,30,31 and hypothermia 32,33,34 , caused by failures in thermoregulation
2018 Jul;52(7):751-762 [2] Samuni Y, Goldstein S, Dean OM, Berk M